Atlas Trials

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

Clinical trial NCT03856853 · UNKNOWN

Trial details

NCT number
NCT03856853
Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)
Start date
2018-06-15
Primary completion
2021-02-10
Enrollment
144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.